Pharmacy News and Stories

Dr. Kavita Nair, PhD, Professor, has been appointed to the Institute for Clinical and Economic Review (ICER) California Technology Assessment Forum independent evidence appraisal council. Over the last decade her primary research interests lie in evaluating the treatment of neurological diseases. Primarily in examining the comparative effectiveness of disease modifying agents used in the management of multiple sclerosis using a combination of several measures to include brain atrophy measurement, clinical cognition, blood biomarkers and patient reported outcomes.

SOP Communications | March 05, 2024

Evidence suggests cannabis may be linked to certain heart problems. Are the risks from smoking marijuana, or is it the THC in weed that could be harmful? “I’m very worried,” said Robert Page, PharmD, “It’s looking like cannabis may be a risk factor for developing cardiovascular disease.”

NBC News | November 18, 2023

“Medicare will begin negotiating prices for top-selling drugs in 2023, but since the United States does not have a public health technology assessment entity that determines comparative effectiveness, the Centers for Medicare & Medicaid Services will need to conduct its own assessments for the drugs being negotiated," said Michael J. DiStefano, PhD.

Newswise | November 07, 2023

A trio of PharmD students set a record this spring, taking fourth place at the American Colleges of Clinical Pharmacy (ACCP) Clinical Research Challenge (CRC) and clinching the highest win for any CU Pharmacy team in the history of the competition.

Jordan Kellerman | July 01, 2023

In an American College of Clinical Pharmacy (ACCP) journals podcast, Dr. Sara Wettergreen, PharmD, speaks on harnessing the power of placebos and mitigating nocebo effects. 

SOP Communications | October 19, 2022